Tumor Ablation Market Size, COVID19 Impact Analysis, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI1870
Tumor Ablation Market size is projected to expand between 2021 and 2027, driven by the increasing burden of cancer in developing countries and rapid innovation of tumor ablation devices worldwide. Furthermore, significant increase in demand for minimally invasive therapies owing to benefits such as patient comfort and speedy recovery, are likely to push the overall market expansion.
Tumor ablation is commonly used for the treatment of tumors formed in lungs, bones, kidneys, and livers. This form of therapy has been gaining widespread adoption among patients who have undergone failed radiotherapy or chemotherapy as well as those who are not surgical candidates. Ablation systems generally consist of a generator or needle-like device that directly provides energy to the targeted tissue to trigger acute cellular necrosis.
On the basis of technology, the radiofrequency ablation segment is poised to expand at an appreciable rate by 2027, on account of its high effectiveness as a treatment for chronic pain relief. RFA is used commonly as a treatment option for patients suffering from chronic pain of various types, particularly neck pain, lower-back pain, as well as arthritis-induced pain due to joint degeneration. Studies suggest that over 70% of patients treated with radiofrequency ablation treatment experience relief from pain, which could, in turn, stimulate radiofrequency market demand during the forecast timeline.
Considering the mode of treatment, the global market from the percutaneous ablation segment will account for a major share. This is the result of the treatment benefits such as rapid recovery, increased safety, cost-efficiency, and minimal scarring, resulting in elevated patient comfort.
Regionally, North America will emerge as a lucrative revenue pocket for the tumor ablation market during the forecast period, given the strong presence of industry players in the U.S. and accelerated introduction of tumor ablation technologies. For instance, in 2020, Cleveland Clinic became the first hospital across the globe to utilize a new, FDA-cleared ablation technology designed to eliminate large tumors on the liver, as part of its Surgical Liver Tumor Ablation Program.
Using a single needle connected to a 150-watt microwave generator, the minimally invasive Emprint™ HP Ablation System with Thermosphere™ Technology designed by Medtronic demonstrated the ability to burn malignant liver tumors measuring as much as 2.4 inches.
The global market is bolstered by the presence of prominent players such as Misonix, NeuWave Medical (Ethicon Inc.), SonaCare Medical, Mermaid Medical, AngioDynamics, EDAP TMS, Galil Medical (Boston Scientific), and Medtronic, among others. Strategic product launch and M&A are among the key efforts employed by the companies to maintain a robust position in the global industry.
For instance, in September 2020, Boston Scientific Corporation inked an investment agreement to acquire Farapulse with an aim to expand access to the company’s PFA (pulsed field ablation) system designed for the treatment of atrial fibrillation and other cardiovascular ailments.
Meanwhile, RFHIC Corporation released the latest 2.4-2.5-GHz, 100-W, CW GaN solid-state generator in October 2020, designed to conduct non-invasive tumor ablation procedures through the usage of microwave energy.
Declining elective procedures amid COVID-19 pandemic & its impact on tumor ablation market trends:
In the wake of the ongoing coronavirus crisis, fundamental changes in the supply chain, consumer behavior, and route to market are knocking several companies off balance. The same can be witnessed in the tumor ablation industry, given the significant decline in the number of newly diagnosed cases of cancer due to the cancellation of non-emergent clinical activities and reduced out-patient clinic visits recommended by the concerned authorities during the pandemic.
However, in certain use-cases, such as for patients with cT3+ tumors, like renal vein or inferior vena cava thrombi, ablative procedures are being considered as an alternative to radical or partial nephrectomy. This allows for shorter inpatient stays and less ventilator usage, while avoiding delays in tumor treatment. Factors such as these could thus provide scope for the market to regain its share globally during the forecast timeline.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability